# US 2009/0263441 A1 · Drug depots having diffreent release profiles for reducing, preventing or treating pain and inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0263441 A1
- Document ID: US20090263441A1
- Status: Published application
- Kind: A1
- Application number: 12/105,994
- Filed: 2008-04-18
- Published: 2009-10-22
- Earliest claimed: 2008-04-18
- Assignees: Warsaw Orthopedic, Inc.
- Inventors: William McKay
- Web page: https://patentgrep.com/patent/US20090263441A1

## CPC

- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.

## Claims

### Claim 1

A plurality of implantable drug depots useful for reducing, preventing or treating pain and/or inflammation in a patient in need of such treatment, the plurality of drug depots comprising a first set of one or more drug depots capable of releasing a therapeutically effective bolus dose of an analgesic and/or an anti-inflammatory agent or pharmaceutically acceptable salts thereof at a site beneath the skin and a second set of one or more drug depots capable of releasing a therapeutically effective amount of the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof over a period of at least three days.

### Claim 2 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein at least one of the second set of drug depot releases the analgesic and/or an anti-inflammatory over a period of 3 days to 6 months.

### Claim 3 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein at least one of the second set of drug depot releases the analgesic and/or an anti-inflammatory over a period of 3 days to 2 weeks.

### Claim 4 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein the one or more drug depots of the first set releases a bolus dose of an analgesic and anti-inflammatory agent.

### Claim 5 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein the first and second set of the drug depots comprise one or more polymer layers containing the analgesic and/or the anti-inflammatory agent.

### Claim 6 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein the analgesic comprises alfentanil, butorphanol, codeine, fentanyl, hydromorphone, levorphanol, meperidine, morphine, sufentanil, tramadol or a combination thereof, and the anti-inflammatory agent comprises clonidine, fluocinolone, dexamethasone, sulindac, sulfasalazine or a combination thereof.

### Claim 7 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein each drug depot of the first and second sets comprises at least one biodegradable polymer comprising one or more of poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-ε-caprolactone, D,L-lactide-glycolide-ε-caprolactone, glycolide-caprolactone, poly(glycolide-,-caprolactone) or a combination thereof.

### Claim 8 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein each drug depot of the first or second set comprises a polymer and the polymer comprises about 20 wt % to about 90 wt % of the drug depot.

### Claim 9 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein at least one drug depot releases about 20% to about 99% of the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof relative to a total amount of the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof loaded in the drug depot over a period of 3 days to 6 months after the drug depot is administered to a target tissue site.

### Claim 10 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof are encapsulated in each drug depot as microparticles, microspheres, microcapsules, and/or microfibers suspended in a gel.

### Claim 11 (depends on 1)

A plurality of implantable drug depots according to claim 1, wherein each drug depot is in the form of one or more pellets.

### Claim 12

A kit comprising a plurality of implantable drug depots useful for reducing, preventing or treating pain and/or inflammation in a patient in need of such treatment, the kit comprising a first set of the plurality of drug depots capable of releasing a therapeutically effective bolus dose of an analgesic and/or an anti-inflammatory agent or pharmaceutically acceptable salts thereof at a site beneath the skin and a second set of the plurality of drug depots capable of releasing a therapeutically effective amount of the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof over a period of at least three days.

### Claim 13 (depends on 12)

A kit according to claim 12, wherein the second set of the plurality of drug depots releases the analgesic and/or an anti-inflammatory over a period of 3 days to 6 months.

### Claim 14 (depends on 12)

A kit according to claim 12, wherein the second set of the plurality of drug depots releases the analgesic and/or an anti-inflammatory over a period of 3 days to 2 weeks.

### Claim 15 (depends on 12)

A kit according to claim 12, wherein the first set of the plurality of drug depots releases a bolus amount of analgesic.

### Claim 16 (depends on 12)

A kit according to claim 12, wherein the first set of the plurality of drug depots releases a bolus amount of anti-inflammatory agent.

### Claim 17

A method of reducing, preventing or treating pain and/or inflammation in a patient in need of such treatment, the method comprising administering a plurality of implantable drug depots at or near a target tissue site beneath the skin of the patient, wherein a first set of the plurality of drug depots is capable of releasing a therapeutically effective bolus dose of an analgesic and/or an anti-inflammatory agent or pharmaceutically acceptable salts thereof and a second set of the plurality of drug depots is capable of releasing a therapeutically effective amount of the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof over a period of at least three days.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the first and second set of the plurality of drug depots are administered to a plurality of target tissue sites that triangulate a pain generator.

### Claim 19 (depends on 17)

A method according to claim 17, wherein the first and/or second set of the plurality of drug depots comprises at least one biodegradable polymer comprising one or more of poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-ε-caprolactone, D,L-lactide-glycolide-ε-caprolactone or a combination thereof.

### Claim 20 (depends on 1)

A method of making an implantable drug depot of claim 1, the method comprising combining a biocompatible polymer and a therapeutically effective amount of the analgesic and/or the anti-inflammatory agent or pharmaceutically acceptable salts thereof and forming the implantable drug depot from the combination.
